Prochlorperazine (Compazine)
Category:
Description:
Indications:
Contraindications:
-
Severe
toxic CNS depression, coma, subcortical brain damage, bone marrow
depression
-
Severe
liver or cardiac disease, narrow-angle glaucoma, pediatric surgery
Precautions:
-
Pregnancy
category C; evidence indicates safety in low doses; expect sedation in
nursing infants
-
Children
<5 years, prolonged use, cardiovascular disease, epilepsy
-
Hepatic
or renal disease, glaucoma, prostatic hypertrophy, severe asthma
-
Emphysema,
hypocalcemia, thyrotoxicosis, tartrazine sensitivity
Adverse
Reactions (Side Effects):
-
CNS:
agitation, anxiety, catatonic-like behavioral states, confusion,
depression, drowsiness, EPS, euphoria, exacerbation of psychotic
symptoms including hallucinations, headache, heat or cold intolerance,
insomnia, lethargy, neuroleptic malignant syndrome, restlessness,
seizures, vertigo
-
CV:
ECG changes, hypertension, hypotension, tachycardia
-
EENT:
blurred vision, cataracts, dry eyes, dry mouth, glaucoma, pigmentaion
of retina or cornea, retinopathy
-
GI:
anorexia, constipation, diarrhea, dyspepsia, hypersalivation, nausea,
vomiting
-
GU:
priapism, urinary retention
-
HEME:
agranulocytosis, anemia, aplastic anemia, hemolytic anemia,
leukocytosis, transient leukopenia
-
METAB:
breast engorgement, gynecomastia, hyperglycemia, hyperprolactinemia,
hypoglycemia, hyponatremia, impotence, increased libido, lactation,
mastalgia, menstrual irregularities
-
RESP:
bronchospasm, increased depth of respiration, laryngospasm
-
SKIN:
diaphoresis, loss of hair, maculopapular and acneiform skin reactions,
photosensitivity
|
Dosage:
Administered
orally, intramuscularly, intravenously, rectally
-
Adult:
-
Antiemetic: PO 5-10mg 3-4 times daily, usual max 40mg daily; PO extended
release 10mg 2 times daily or 15mg once daily; IM 5-10mg every 3-4
hours, usual max 40mg daily; IV 2.5-10mg every 3-4 hours, max 10mg
per dose, 40 mg/day; PR 25mg 2 times daily
-
Psychosis: PO 5-10mg 3-4 times daily, increase dose as needed, max 150mg
daily; IM 10-20mg every 4 hours as needed, convert to PO as soon
as possible
-
Child:
-
Antiemetic: PO/PR 9-14kg: 2.5mg every 12 –24 hours, max 7.5mg daily;
14-18kg: 2.5mg every 8 hours or 5mg every 12 hours, max 15mg
daily; IM 0.1-0.5 mg/kg/dose, convert to PO as soon as possible
-
Psychosis: PO/PR 2-12 years: 2.5mg 2-3 times daily, increase dose as
needed, max 20mg daily; 2-5 years: 25mg daily; IM 6-12 years: 0.13
mg/kg/dose, convert to PO as soon as possible
Drug
interactions:
· Levodopa:
inhibited effect of levodopa on Parkinson’s disease
· Indomethacin:
possible increased CNS side effects, other NSAIDs less likely to have
effect
· Narcotic
analgesics: excessive CNS depression, hypotension, respiratory depression
|
Home
· Military Medicine
· Sick Call · Basic Exams
· Medical Procedures
· Lab and X-ray · The Pharmacy
· The Library · Equipment
· Patient Transport
· Medical Force
Protection · Operational Safety · Operational
Settings · Special
Operations · Humanitarian
Missions · Instructions/Orders · Other Agencies · Video Gallery
· Forms · Web Links · Acknowledgements
· Help · Feedback Approved for public release;
Distribution is unlimited. The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.
Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.
Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300 |
Operational Medicine
Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
January 1, 2001 |
United States Special Operations
Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323 |
*This web version is provided by The Brookside Associates, LLC. It contains
original contents from the official US Navy NAVMED P-5139, but has been
reformatted for web access and includes advertising and links that were not
present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the
Department of the Navy or the Department of Defense. The presence of any
advertising on these pages does not constitute an endorsement of that product or
service by either the US Department of Defense or the Brookside Associates. The
Brookside Associates is a private organization, not affiliated with the United
States Department of Defense.
© 2015, Brookside Associates, LLC. All rights reserved
Other Brookside Products
|
|